Loading
Inflammasome and Immune Disorders · Journal article
Aposta · July 22, 2026
Encouraging direction, but not yet definitive.
This single-centre RCT reports that early colchicine treatment (2 mg loading dose then 0.5 mg twice daily for 5 days) significantly improves left ventricular ejection fraction and reduces myocardial injury markers in acute anterior-wall STEMI patients at 30 days. The results suggest a potential cardioprotective effect, but the lack of clinical outcome data (mortality, rehospitalization, heart failure) and short follow-up period limit conclusions about clinical practice impact.
Randomized controlled trial. 126 patients with acute anterior-wall ST-segment elevation myocardial infarction presenting to Cardiology Department; baseline demographic and clinical characteristics comparable between groups. Intervention: Colchicine: 2 mg loading dose followed by 0.5 mg twice daily for five days in addition to guideline-directed medical therapy. Compared with: Standard guideline-directed medical therapy alone. n = 126. Sheikh Zayed Hospital, Lahore.
Mean LVEF at 30 days was 50.4 ± 6.1% with colchicine vs. 46.2 ± 6.4% with control (p<0.001) LVEF improvement was 7.3 ± 3.4% with colchicine vs. 3.4 ± 2.8% with control (p<0.001) Peak troponin-I was 28.9 ± 10.8 ng/mL with colchicine vs. 34.6 ± 12.1 ng/mL with control (p=0.006)
Hospital stay duration mentioned in conclusion but actual data not provided in results; no hard clinical endpoints (mortality, reinfarction, heart failure admission) reported
If confirmed in larger, multicentre, adequately blinded trials with clinical endpoints, early colchicine administration could represent a novel adjunctive strategy to preserve cardiac function in acute anterior-wall STEMI. Current evidence supports surrogate improvement but does not yet justify routine clinical adoption without demonstration of reduced mortality or heart failure hospitalizations.
Randomized controlled trial showing statistically significant improvement in LVEF and reduced myocardial injury markers with early colchicine in acute anterior-wall STEMI, but limited by single-centre design, short follow-up, and lack of hard clinical endpoints.
As stated by the source record.
Quoted from the source exactly as published.
If confirmed in larger, multicentre, adequately blinded trials with clinical endpoints, early colchicine administration could represent a novel adjunctive strategy to preserve cardiac function in acute anterior-wall STEMI. Current evidence supports surrogate improvement but does not yet justify routine clinical adoption without demonstration of reduced mortality or heart failure hospitalizations.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background: Acute anterior-wall ST-segment elevation myocardial infarction (STEMI) is associated with extensive myocardial injury, adverse left ventricular remodeling, and reduced left ventricular ejection fraction (LVEF), resulting in increased morbidity and mortality. Objective: To evaluate the effect of early colchicine administration on preservation of left ventricular ejection fraction in patients with acute anterior-wall ST-segment elevation myocardial infarction. Methodology: This randomized controlled trial was conducted in Cardiology Department, Sheikh Zayed Hospital Lahore from March 2026 to June 2026, including 126 patients with acute anterior-wall STEMI, who were equally allocated into colchicine (n=63) and control (n=63) groups. The colchicine group received a 2 mg loading dose followed by 0.5 mg twice daily for five days in addition to guideline-directed medical therapy, whereas the control group received standard therapy alone. Results: Baseline demographic and clinical characteristics were comparable between the two groups. At 30 days, mean LVEF was significantly higher in the colchicine group than in the control group (50.4 ± 6.1% vs. 46.2 ± 6.4%; p<0.001). Improvement in LVEF was also greater with colchicine (7.3 ± 3.4% vs. 3.4 ± 2.8%; p<0.001). Peak troponin-I (28.9 ± 10.8 vs. 34.6 ± 12.1 ng/mL; p=0.006) and CK-MB (168.5 ± 52.7 vs. 192.8 ± 58.4 U/L; p=0.02) were significantly lower in the colchicine group. Preserved LVEF (≥50%) was achieved in 76.2% of colchicine-treated patients compared with 60.3% of controls (p=0.049). Conclusion: Early colchicine administration significantly improved left ventricular systolic function, reduced myocardial injury, and shortened hospital stay in patients with acute anterior-wall STEMI.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.